Digital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
About This Group of Stocks
Our Expert Thinking
Digital therapeutics represent a fundamental shift in healthcare delivery. These clinically-validated software programs are designed to prevent, manage, or treat medical conditions without traditional drugs or devices. As healthcare embraces technology, these scalable solutions promise better patient outcomes at lower costs.
What You Need to Know
This is an emerging, high-growth sector with significant potential but also substantial risk. Insurance reimbursement is the critical catalyst for widespread adoption. Companies range from pure-play digital therapeutics developers to larger telehealth platforms incorporating these technologies into broader offerings.
Why These Stocks
We've selected companies directly involved in creating or delivering software-based medical treatments. This includes dedicated digital therapeutics developers, telehealth platforms enabling digital prescriptions, and companies creating complementary technologies that support this emerging ecosystem.
Why You'll Want to Watch These Stocks
Software Is Becoming Medicine
These companies are creating FDA-cleared apps that actually treat diseases. It's a whole new category of medicine where code itself becomes the treatment—potentially reaching millions of patients at a fraction of traditional costs.
Insurance Companies Are Paying Up
The big breakthrough? Insurance providers are increasingly willing to reimburse for these digital therapies. This payment validation could trigger explosive growth as these treatments become mainstream healthcare options.
Early Days of a Healthcare Revolution
We're just at the beginning of software-as-medicine. With chronic diseases, mental health conditions, and preventative care all being targeted, these companies are pioneering what could become a multi-billion dollar healthcare category.
